Research Analysts Offer Predictions for EBS Q2 Earnings

Emergent BioSolutions Inc. (NYSE:EBS - Free Report) - HC Wainwright reduced their Q2 2025 EPS estimates for Emergent BioSolutions in a research report issued to clients and investors on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will earn ($0.26) per share for the quarter, down from their previous estimate of ($0.18). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Emergent BioSolutions' current full-year earnings is ($0.63) per share. HC Wainwright also issued estimates for Emergent BioSolutions' Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at $0.24 EPS and FY2026 earnings at $3.82 EPS.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.71 earnings per share for the quarter, topping analysts' consensus estimates of $0.49 by $0.22. The business had revenue of $222.20 million for the quarter, compared to analysts' expectations of $218.50 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%.

Separately, Wall Street Zen cut Emergent BioSolutions from a "buy" rating to a "hold" rating in a report on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Shares of EBS stock traded down $0.10 during trading hours on Monday, hitting $6.40. The company's stock had a trading volume of 1,179,900 shares, compared to its average volume of 1,854,243. The business has a fifty day moving average of $5.24 and a 200-day moving average of $7.71. The stock has a market cap of $347.38 million, a price-to-earnings ratio of -1.56 and a beta of 2.09. Emergent BioSolutions has a twelve month low of $4.02 and a twelve month high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions declared that its Board of Directors has authorized a share buyback plan on Monday, March 31st that authorizes the company to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 19% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company's leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the sale, the director now owns 101,100 shares in the company, valued at $589,413. This trade represents a 25.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of Emergent BioSolutions

Hedge funds have recently added to or reduced their stakes in the business. Covestor Ltd boosted its stake in Emergent BioSolutions by 5,458.5% in the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 2,893 shares during the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth approximately $63,000. E Fund Management Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth approximately $98,000. EP Wealth Advisors LLC acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth approximately $110,000. Finally, Alpine Global Management LLC acquired a new stake in shares of Emergent BioSolutions in the fourth quarter worth approximately $112,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.